Use of allogeneic stem cell transplantation for moderate-severe Glanzmann thrombasthenia. Platelets 2015;26(7):702-4
Date
12/31/2014Pubmed ID
25548835DOI
10.3109/09537104.2014.987225Scopus ID
2-s2.0-84940724421 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Glanzmann thrombasthenia (GT) is a rare, autosomal recessive coagulopathy characterized by either qualitative or quantitative abnormalities of the membrane glycoprotein αIIbβ3 complex leading to bleeding tendencies, ranging from purpura to life-threatening hemorrhage. Although patients can be managed with supportive measures including platelet transfusions, complications such as alloimmunization are possible. Allogeneic stem cell transplantation (ASCT) can be indicated in severe cases of GT. We report the case of an eight-month-old girl diagnosed with moderate-severe GT, who was successfully treated with a reduced-intensity, human leukocyte antigen (HLA)-identical ASCT.
Author List
Walz A, Lenzen A, Curtis B, Canner J, Schneiderman JAuthor
Brian Curtis PhD Director in the Platelet & Neutrophil Immunology Laboratory department at BloodCenter of WisconsinMESH terms used to index this publication - Major topics in bold
Blood PlateletsFemale
HLA Antigens
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Infant
Severity of Illness Index
Siblings
Thrombasthenia
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome
